Author

Francois Lamontagne

Universit

Biography

Dr. Francois Lamontagne is currently working in Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Title
Cited by
Year
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier, YA Cavayas, ...Cmaj 194 (7), E242-E251, 2022202
90
2022
Intravenous vitamin C in adults with sepsis in the intensive care unit
F Lamontagne, MH Masse, J Menard, S Sprague, R Pinto, DK Heyland, ...New England Journal of Medicine 3 (25), 2387-2398, 2022202
86
2022
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial
CA Bradbury, PR Lawler, SJ Stanworth, BJ McVerry, Z McQuilten, ...JAMA-Journal of the American Medical Association 327 (13), 1247-1259, 2022202
57
2022
Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium …
LF Reyes, S Murthy, E Garcia-Gallo, M Irvine, L Merson, I Martin-Loeches, ...ERJ open research 8 (1), 2022202
37
2022
Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ...Jama 3 (1), 39-51, 2023202
29
2023
The value of open-source clinical science in pandemic response: lessons from ISARIC
A Abbas, SA Abdukahil, NN Abdulkadir, R Abe, L Abel, L Absil, S Acharya, ...The Lancet Infectious Diseases 21 (12), 1623-1624, 2021202
26
2021
Longitudinal plasma proteomics analysis reveals novel candidate biomarkers in acute COVID-19
Y Mohammed, DR Goodlett, MP Cheng, DC Vinh, TC Lee, A Mcgeer, ...Journal of proteome research 21 (4), 975-992, 202
22
2022
Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis
Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-: systematic review and network meta-analysisD Zeraatkar, E Cusano, JPD Martínez, A Qasim, S Mangala, E Kum, ...BMJ medicine 1 (1), 2022202
19
2022
Parenteral vitamin C in patients with severe infection: a systematic review
A Agarwal, J Basmaji, SM Fernando, FZ Ge, Y Xiao, H Faisal, ...NEJM Evidence 1 (9), EVIDoa2200105, 2022202
17
2022
Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19
EC Goligher, PR Lawler, TP Jensen, V Talisa, LR Berry, E Lorenzi, ...JAMA 329 (13), 1066-1077, 2023202
11
2023
WHO Living Guidelines on antivirals for COVID-19 are evidence-based
WHO Living Guidelines on antivirals for COVID-1 are evidence-basedA Owen, JV Diaz, G Guyatt, F Lamontagne, M Stegemann, PO Vandvik, ...The Lancet 400 (1036), 216-218, 2022202
9
2022
ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19
M Etienne, N Ettalhaoui, AG Everding, M Evers, I Fabre, M Fabre, ...Scientific data 9 (1), 454, 2022202
8
2022
Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19
GLY Rocheleau, T Lee, Y Mohammed, D Goodlett, K Burns, MP Cheng, ...Critical Care Medicine 50 (9), 1306, 2022202
7
2022
Vitamin C in sepsis
PJ Young, F Lamontagne, T FujiiIntensive Care Medicine 48 (11), 1621-1624, 2022202
5
2022
A Bayesian reanalysis of the standard versus accelerated initiation of renal-replacement therapy in acute kidney injury (STARRT-AKI) trial
FG Zampieri, BR da Costa, ST Vaara, F Lamontagne, B Rochwerg, ...Critical Care 26 (1), 1-10, 2022202
4
2022
Lower versus higher exposure to vasopressor therapy in vasodilatory hypotension: a systematic review with meta-analysis
A Richards-Belle, M Hylands, F Muttalib, S Taran, B Rochwerg, A Day, ...Critical Care Medicine 51 (2), 25, 2023202
4
2023
Quality Indicators Targeting Low-Value Clinical Practices in Trauma Care
L Moore, M Bérubé, PA Tardif, F Lauzier, A Turgeon, P Cameron, ...JAMA surgery 157 (6), 507-51, 2022202
4
2022
Research interrupted: applying the CONSERVE 2021 Statement to a randomized trial of rehabilitation during critical illness affected by the COVID-19 pandemic
JC Reid, A Molloy, G Strong, L Kelly, H O’Grady, D Cook, PM Archambault, ...Trials 23 (1), 735, 2022202
4
2022
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized …
S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ...JAMA 329 (1), 1183-1196, 2023202
4
2023
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients
J Baruch, A Rojek, C Kartsonaki, BKT Vijayaraghavan, BP Gonçalves, ...Influenza and other respiratory viruses 16 (6), 1040-1050, 2022202
3
2022

Referred From: https://scholar.google.com/citations?hl=en&user=O_ZV7I4AAAAJ

Cited by
Citations 23753
h-index 64
i10-index 169
Recommended Journals
Open Access Journals